M
500.39
1.22 (0.24%)
| Previous Close | 499.17 |
| Open | 495.03 |
| Volume | 242,106 |
| Avg. Volume (3M) | 364,336 |
| Market Cap | 11,364,568,064 |
| Price / Sales | 14.45 |
| Price / Book | 17.51 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -123.38% |
| Operating Margin (TTM) | -57.79% |
| Diluted EPS (TTM) | -17.83 |
| Total Debt/Equity (MRQ) | 16.85% |
| Current Ratio (MRQ) | 5.91 |
| Operating Cash Flow (TTM) | -395.31 M |
| Levered Free Cash Flow (TTM) | -274.11 M |
| Return on Assets (TTM) | -25.56% |
| Return on Equity (TTM) | -50.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Madrigal Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
0.3
| Analyst Consensus | 4.0 |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.30 |
|
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 7.73% |
| % Held by Institutions | 108.28% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 964.00 (Barclays, 92.65%) | Buy |
| Median | 660.00 (31.90%) | |
| Low | 587.00 (Canaccord Genuity, 17.31%) | Buy |
| Average | 722.00 (44.29%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 540.56 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 28 Jan 2026 | 964.00 (92.65%) | Buy | 496.54 |
| Citizens | 20 Jan 2026 | 745.00 (48.88%) | Buy | 504.95 |
| Piper Sandler | 19 Dec 2025 | 900.00 (79.86%) | Buy | 591.02 |
| B. Riley Securities | 11 Dec 2025 | 670.00 (33.90%) | Buy | 571.33 |
| HC Wainwright & Co. | 21 Nov 2025 | 620.00 (23.90%) | Buy | 547.96 |
| 11 Nov 2025 | 568.00 (13.51%) | Buy | 541.50 | |
| Oppenheimer | 20 Nov 2025 | 650.00 (29.90%) | Buy | 542.12 |
| Truist Securities | 19 Nov 2025 | 640.00 (27.90%) | Buy | 555.60 |
| Canaccord Genuity | 13 Nov 2025 | 587.00 (17.31%) | Buy | 514.93 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HUNTSMAN CAROLE | - | 499.17 | -910 | -454,245 |
| LEVY RICHARD S | - | - | 0 | 0 |
| SIBOLD WILLIAM JOHN | - | 499.17 | -1,577 | -787,191 |
| TAUB REBECCA | - | 499.17 | -647 | -322,963 |
| Aggregate Net Quantity | -3,134 | |||
| Aggregate Net Value ($) | -1,564,399 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 499.17 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TAUB REBECCA | Director | 26 Jan 2026 | Sell (-) | 647 | 499.17 | 322,963 |
| SIBOLD WILLIAM JOHN | Officer | 26 Jan 2026 | Sell (-) | 1,577 | 499.17 | 787,191 |
| HUNTSMAN CAROLE | Officer | 26 Jan 2026 | Sell (-) | 340 | 499.17 | 169,718 |
| HUNTSMAN CAROLE | Officer | 26 Jan 2026 | Automatic sell (-) | 570 | 499.17 | 284,527 |
| LEVY RICHARD S | Director | 26 Jan 2026 | Option execute | 4,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |